Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
2(20%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
9
90%
Ph early_phase_1
1
10%

Phase Distribution

10

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution10 total trials
Early Phase 1First-in-human
1(10.0%)
Phase 1Safety & dosage
9(90.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

10

all time

Status Distribution
Active(2)
Completed(1)
Other(7)

Detailed Status

unknown7
Recruiting1
Completed1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
2
Success Rate
100.0%
Most Advanced
Phase 1

Trials by Phase

Early Phase 11 (10.0%)
Phase 19 (90.0%)

Trials by Status

recruiting110%
completed110%
active_not_recruiting110%
unknown770%

Recent Activity

2 active trials
Showing 5 of 10
completedphase_1

Evaluate the Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With R/R B-ALL

NCT05350787
active_not_recruitingearly_phase_1

Efficacy, Safety, and Pharmacokinetics of ThisCART19A Combined With Olverembatinib in Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.

NCT07074496
recruitingphase_1

CAR-T for Autoimmune Hemolytic Anemia Patients Who Have Failed Three or More Lines of Therapy

NCT06212154
unknownphase_1

Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With Refractory or Relapsed B Cell Lymphoma

NCT05776407
unknownphase_1

Assessment of Safety and Efficacy of ThisCART19A in Adult Patients With B Cell Malignancies After Failure of Autologous Chimeric Antigen Receptor T- Cell(CAR-T) Therapy

NCT05640713
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT05350787Phase 1

Evaluate the Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With R/R B-ALL

Completed
NCT07074496Early Phase 1

Efficacy, Safety, and Pharmacokinetics of ThisCART19A Combined With Olverembatinib in Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.

Active Not Recruiting
NCT06212154Phase 1

CAR-T for Autoimmune Hemolytic Anemia Patients Who Have Failed Three or More Lines of Therapy

Recruiting
NCT05776407Phase 1

Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With Refractory or Relapsed B Cell Lymphoma

Unknown
NCT05640713Phase 1

Assessment of Safety and Efficacy of ThisCART19A in Adult Patients With B Cell Malignancies After Failure of Autologous Chimeric Antigen Receptor T- Cell(CAR-T) Therapy

Unknown
NCT05576181Phase 1

Safety and Efficacy of ThisCART19A Bridging Hematopoietic Stem Cell Transplantation in Patients With Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia

Unknown
NCT05535673Phase 1

Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With Refractory or Relapsed B Cell Lymphoma

Unknown
NCT05350852Phase 1

Evaluate the Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With MRD+ B-ALL

Unknown
NCT05349266Phase 1

Assessment of Safety and Efficacy of ThisCART19A in Adult Patients With B-NHL After Failure of Autologous Chimeric Antigen Receptor T- Cell(CAR-T) Therapy

Unknown
NCT05340829Phase 1

Evaluate the Safety and Effect of ThisCART19A in Patients With AIDS Related B Cell Lymphoma/Lympholeukemia

Unknown

All 10 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
10